Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has convened its 2026 second extraordinary general meeting (EGM) for 2:00 p.m. on 25 June 2026. The hybrid session will be held physically at the company’s Beijing headquarters (12 Baoshen South Street, Daxing Bio-Medicine Industry Park) and concurrently online via the eVoting Portal.
Key resolutions to be tabled:
1. Remuneration Governance • Ordinary resolution to adopt a new “Remuneration Management System for Directors and Senior Management”.
2. H-Share Repurchase Mandate (Special Resolution) • Board to receive a general mandate to repurchase up to 10% of issued H Shares during the “Relevant Period”, capped at approximately 2.48 % of the company’s total issued share capital as at the EGM date. • Execution is subject to (i) shareholder approval, (ii) regulatory clearance in the PRC and Hong Kong, and (iii) creditor-notification procedures under PRC Company Law. • The Board will be empowered to set repurchase price, volume and timing; cancel or hold repurchased shares as treasury stock; and amend the Articles of Association to reflect any capital reduction.
3. General Mandate to Issue H Shares (Special Resolution) • Board authorization to allot, issue or deal with additional H Shares—ordinary shares and/or convertible securities—up to 10% of the company’s total issued share capital (A Shares and H Shares, excluding any treasury shares) as at the EGM approval date. • The mandate extends to the sale or transfer of treasury shares. • All issuances remain subject to compliance with PRC Company Law, PRC Securities Law, the Measures for the Administration of Registration of Securities Issuance by Listed Companies, Hong Kong Listing Rules and other regulatory requirements.
4. Credit Facilities and Guarantees • Proposal to apply for comprehensive credit lines and to provide related guarantees for the company and its subsidiaries.
Shareholder Logistics • H-share register closure: 22–25 June 2026 (both days inclusive). Transfers must be lodged by 4:30 p.m., 18 June 2026, with Tricor Investor Services Limited for eligibility. • Shareholders may attend in person or online and vote via the designated portal using credentials supplied by the registrar. All resolutions will be decided by poll.
Board Composition (as of 4 June 2026) Chairman, CEO & Executive Director: Dr. Shen Yuelei Executive Directors: Dr. Ni Jian Non-Executive Directors: Dr. Zhou Kexiang, Ms. Zhang Leidi, Dr. Liu Hongkang Independent Non-Executive Directors: Mr. Hua Fengmao, Dr. Yu Changyuan, Ms. Liang Xiaoyan Employee Director: Ms. Li Yan
The full circular and meeting materials are available on the Hong Kong Stock Exchange (www.hkexnews.hk) and the company’s website (www.biocytogen.com.cn).
Comments